The p53 tumor suppressor pathway is a complex network of signals that fluctuate to regulate cell proliferation and death. Mdm2 and Mdm4 are crucial inhibitors of p53 and are often present at high levels in tumors thus dampening p53 activity eliminating the need for p53 mutations. Mdm2 also has p53-independent functions that promote chromosomal instability. Biochemical data indicated that Mdm2 and Mdm4 also bind p73, a p53 related protein. We have identified physiologically important interactions of Mdm2 with p73 in vivo. Thus, our overarching hypothesis is that the oncogenic functions of the Mdm proteins are a combined effect of inhibiting p53 and p73 functions. Furthermore, because normal cells, unlike tumor cells, do not tolerate high levels of Mdm2, we also hypothesize that tumor-specific changes alter cell physiology to tolerate high Mdm2 levels. To test these hypotheses, we will decipher the intricate relationship between p73 and Mdm2 by studying the phenotype of Mdm2-/-p73-/- mice. In addition, we will cross tumor prone Mdm2 transgenic and SNP309 mice (with higher than normal Mdm2 levels) with p73 mice to examine effects of concomitant p73 loss on chromosomal aberrations and tumor phenotypes.
In aim 2, we will determine the physiological relevance of the Mdm4/p73 interactions, and we will generate p73 heterozygous Mdm4 transgenic mice to examine the importance of this combination on a tumor phenotype. Lastly, we will identify factors that allow tumor (but not normal) cells to tolerate high Mdm2 levels using genetic screens.

Public Health Relevance

We have identified physiologically relevant interactions between the tumor suppressor and p53-related protein, p73, and an inhibitor Mdm2. These studies will define new functional relationships and components of the p53 tumor suppressor pathway, thus expanding the number of possible drug targets for therapeutic strategies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Cancer Genetics Study Section (CG)
Program Officer
Watson, Joanna M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
Other Domestic Higher Education
United States
Zip Code
Xiong, Shunbin; Pant, Vinod; Zhang, Yun et al. (2017) The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis. J Pathol 241:501-510
Pant, Vinod; Larsson, Connie A; Aryal, Neeraj et al. (2017) Tumorigenesis promotes Mdm4-S overexpression. Oncotarget 8:25837-25847
Pant, V; Xiong, S; Chau, G et al. (2016) Distinct downstream targets manifest p53-dependent pathologies in mice. Oncogene 35:5713-5721
Riley, M F; You, M J; Multani, A S et al. (2016) Mdm2 overexpression and p73 loss exacerbate genomic instability and dampen apoptosis, resulting in B-cell lymphoma. Oncogene 35:358-65
Mancini, F; Pieroni, L; Monteleone, V et al. (2016) MDM4/HIPK2/p53 cytoplasmic assembly uncovers coordinated repression of molecules with anti-apoptotic activity during early DNA damage response. Oncogene 35:228-40
Tashakori, Mehrnoosh; Zhang, Yun; Xiong, Shunbin et al. (2016) p53 Activity Dominates That of p73 upon Mdm4 Loss in Development and Tumorigenesis. Mol Cancer Res 14:56-65
Eischen, Christine M; Lozano, Guillermina (2014) The Mdm network and its regulation of p53 activities: a rheostat of cancer risk. Hum Mutat 35:728-37
Pant, Vinod; Lozano, Guillermina (2014) Limiting the power of p53 through the ubiquitin proteasome pathway. Genes Dev 28:1739-51
Zhang, Yun; Xiong, Shunbin; Li, Qin et al. (2014) Tissue-specific and age-dependent effects of global Mdm2 loss. J Pathol 233:380-91
Li, Qin; Zhang, Yun; El-Naggar, Adel K et al. (2014) Therapeutic efficacy of p53 restoration in Mdm2-overexpressing tumors. Mol Cancer Res 12:901-11

Showing the most recent 10 out of 24 publications